Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial

Abstract Background Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin a...

Full description

Bibliographic Details
Main Authors: Gian Paolo Fadini, Benedetta Maria Bonora, Giancarlo Zatti, Nicola Vitturi, Elisabetta Iori, Maria Cristina Marescotti, Mattia Albiero, Angelo Avogaro
Format: Article
Language:English
Published: BMC 2017-04-01
Series:Cardiovascular Diabetology
Subjects:
Atherosclerosis
Body composition
Therapy
Online Access:http://link.springer.com/article/10.1186/s12933-017-0529-3

Internet

http://link.springer.com/article/10.1186/s12933-017-0529-3

Similar Items